Across a range of genetically engineered, patient-derived and orthoptic NSCLC models, [18F]FSPG retention increased in tumours with NRF2 activation compared to those with a normal-functioning NRF2/KEAP1 axis. The gene discussed is NFE2L2; the disease is non-small cell lung carcinoma.